Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Banking On Exubera Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm acquires Sanofi-Aventis’ rights to the inhaled insulin product through a change-in-control clause.
Advertisement

Related Content

VCs Think Twice About Type 2 Diabetes Investments
VCs Think Twice About Type 2 Diabetes Investments
Sanofi's Diabetes Sales Force Increase Not Due To Threat From Exubera Or Levemir, Exec Says
Sanofi's Diabetes Sales Force Increase Not Due To Threat From Exubera Or Levemir, Exec Says
Exubera Approved In Europe One Day Before U.S. User Fee Date
Exubera Approved In Europe One Day Before U.S. User Fee Date
Exubera User Fee Deadline Extended By Three Months
Exubera User Fee Deadline Extended By Three Months
Pfizer/Sanofi Exubera Effective For Both Type 1 And Type 2 Diabetes, Committee Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS063041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel